BLOOD LEVELS OF GLIAL-DERIVED NEUROTROPHIC FACTOR IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE RELATIONSHIP WITH THE NEUROPATHIC COMPONENT OF THE PAIN SYNDROME
Kedyk I.O., Stanislavchuk M.A.
Summary. Introduction. A promising direction for the study of the pathogenesis of ankylosing spondylitis is the study of the role of GDNF, which has not been studied to date. Aim: to study the characteristics of GDNF levels in ankylosing spondylitis depending on the presence and absence of neuropathic pain, and to evaluate the relationship of GDNF with markers of neuropathic pain and clinical manifestations of the disease. Materials and methods. The level of GDNF in the blood plasma of 65 patients with ankylosing spondylitis was clinically examined and measured (33 with neuropathic pain and 32 without). Results. A significantly lower level of GDNF was found in patients with neuropathic pain: 2.64±1.17 pg/ml versus 4.34±2.94 pg/ml (p=0.031), and a correlation between GDNF content and body weight was established (rS=0.389, p=0.001), body mass index (rS=0.328, p=0.008), markers of neuropathic pain (LANNS (rS=–0.253, p=0.042), DN4 (rS=–0.308, p=0.013)), BAS-G 6 months (rS=–0.269, p=0.029), BAS-G average (rS=–0.265, p=0.033), and depression index (rS=–0.293, p=0.018). Also, in a patient with a reduced level of GDNF, slightly higher the disease activity, worse health status and quality of life were found. Conclusions. A lover level of GDNF in patients with AS is associated with the neuropathic component of the pain syndrome, higher disease activity, worse functional capacity, quality of life and mental state of patients.
Leave a comment